MindRank utilizes a proprietary AI platform integrating machine learning, biology, and chemistry to accelerate small molecule drug discovery. The company focuses on developing novel drugs with superior potency and druggability, particularly targeting hard-to-drug molecular targets. This approach has resulted in advancing an AI-designed small molecule drug into Phase III clinical trials for obesity and type 2 diabetes.
Funding
Funding not disclosed
Founders
Product
Problem
Discovering small molecule drugs for traditionally undruggable molecular targets is a slow and challenging process, often requiring extensive time and resources. Traditional methods struggle to efficiently identify novel compounds with optimal potency, druggability, and safety profiles.
Solution
MindRank offers an AI-powered platform, Molecule Pro™, designed to accelerate the discovery of small molecule drugs, particularly for hard-to-drug targets. The platform integrates innovations in machine learning, biology, and chemistry to systematically engineer molecules with improved characteristics. By leveraging AI, MindRank aims to transform low-probability drug discovery events into high-probability successes, delivering novel therapeutics with superior potency and druggability.
Target Audience
MindRank's primary customers are biopharmaceutical companies seeking to accelerate their drug discovery programs and develop novel therapeutics for challenging molecular targets.
Features
- AI-driven platform for small molecule drug discovery
- Focus on hard-to-drug molecular targets
- Proprietary algorithms for optimizing potency, druggability, and novelty
- Demonstrated success with MDR-001, an oral small-molecule GLP-1 RA, achieving US IND approval in 19 months
- Capabilities in identifying allosteric inhibitors with best-in-class potential